Oana Danciu
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (NCT05467891) | Oana Danciu | 2022-09-13 |
Track Oana Danciu automatically
Every clearance here is in the API, with alerts when new ones post.